Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC

Conditions

oligometastatic pancreatic cancer

Brief summary

Overall Survival (OS): Time from randomization to death from any cause or EOS

Detailed description

Progression-free survival (PFS): Time of randomization to cancer progression or death or EOS, Procedure related complications and mortality, Quality of life (EORTC QLQ-C30, PAN-26, CIPN20), Quality-adjusted Time without Symptoms and Toxicity (Q-TWIST) Assessment of safety, General safety of surgical removal of tumor and metastases in patients with oligometastatic pancreatic cancer

Ghadimi M, Pelzer U, Besselink MG, Siveke J, Telgmann R, Braren R, Wilmink H, Crede M, Koenig A, Koenig U, Liffers ST, Antweiler K, Uijterwijk B, Seppanen H, Nordin A, Puolakkainen P, Dajani OF, Labori KJ, Johansson M, Bratlie SO, Friede T, Jo P.

2025-02-063 citations

10.1186/s12885-025-13573-7

METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: Multimodal surgical treatment versus systemic chemotherapy alone—A prospective randomized controlled multicenter phase III trial.

Peter Jo, Michael Ghadimi, Uwe Pelzer, Marie-Theres Andrea Crede, Ralph Telgmann et al. (10 authors)

Journal of Clinical Oncology2024-06-015 citations

10.1200/jco.2024.42.16_suppl.tps4207

Interventions

DRUGIrinotecan

DRUGFluorouracil

DRUGCalcium Folinate

DRUGOxaliplatin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS): Time from randomization to death from any cause or EOS	—

Secondary

Measure	Time frame
Progression-free survival (PFS): Time of randomization to cancer progression or death or EOS, Procedure related complications and mortality, Quality of life (EORTC QLQ-C30, PAN-26, CIPN20), Quality-adjusted Time without Symptoms and Toxicity (Q-TWIST) Assessment of safety, General safety of surgical removal of tumor and metastases in patients with oligometastatic pancreatic cancer	—

Countries

Finland, Germany, Netherlands, Sweden

Outcome results

None listed